|Parkinson's Measurement||Home PDMeasure Postings Data Studies Tools Philosophy Contact|
|Research by PwP for PwP||NEW... PDMeasure: integrated survey and test environment. See.|
This page is for people with Parkinson's (PwP). It calculates the contribution made by each of your Parkinson's drugs, using, as a common denominator, an estimate of the levodopa equivalent dose (LED). The LED is the amount of levodopa (taken with carbidopa) that has a similar effect as the drug taken. Adding together all the LEDs in a day gives the levodopa equivalent daily dose (LEDD).
To find your LEDD, enter your data in the green boxes. Where a drug contains levodopa and other active components, input the levodopa dose only. Then press the blue "Calculate" button.
The conversion factors used are shown in the table below. Where the literature shows large variations in what is thought to be the correct conversion factor to use, a tuple is shown meaning (lowest estimate/highest estimate/average estimate)
|Drug||Conv Factor||Sources and Notes|
|Azilect||10||Brand name of rasagiline.|
|Entacapone|| 0.33*L-Dopa. Enter Levodopa with Entacapone|
|Levodopa with Entacapone||1.33||Inferred from *.|
|Levodopa with Tolcapone||1.5||Inferred from *.|
|Madopar||1||Brand name of levodopa and benserazide.*|
|Mirapex||100||Brand name of pramipexole|
|Rasagiline||100|| Maximum effect found with 1mg.|
|Requip||20||Brand name of ropinirole|
|RequipXL||20||Inferred from . Brand name of ropinirole CR|
|Rytary||0.6||Estimate based on , Table 1, Conversion from Immediate-Release Carbidopa-Levodopa to Rytary.*|
|Sinemet||1||Brand name of levopdopa with carbidopa.*|
|SinemetCR||0.75||Brand name of controlled release levopdopa with carbidopa.*|
|Tolcapone|| 0.5*L-Dopa. Enter Levodopa with Tolcapone|
Note *: This drug contains multiple components. Input the levodopa dose only.
The conversion factors are clearly rounded which shows that they are estimates.
Different sources give different conversion factors. The range of the estimates for ropinirole, a factor of two, is especially large.
The analysis does not take into account the timing of the doses, differences in effectiveness from person to person, the time it takes a drug to have an effect and the duration of its activity.
 "Levodopa Dose Equivalency: A Systematic Review"
Dr Claire Smith, Birmingham Clinical Trials Unit
8th June 2010
Smith et al.
 GSK prescribing information for RequipXL
RequipXL prescribing information
 Rytary prescribing information
Rytary prescribing information